HER-2 Gene: This Aggressive Breast Cancer Requires Targeted Treatment

Breast Cancer
Print icon

Click here for a callback from a breast health nurse navigator.

All breast cancers are not structured, and therefore not treated, the same, which is why doctors test tissue removed during biopsies to determine the type and stage of the disease.

All tissue is also tested for what is called the HER-2 gene, according to Dr. Stacy Nerenstone, a breast oncologist with the Hartford HealthCare Cancer Institute who is particularly interested in treating patients who test positive for what is a more aggressive form of breast cancer.

“HER-2 positive breast cancer affects 15 percent of patients,” she said. “Women with both early- and later-stage disease need to be treated with an agent that is directly targeted to that genetic marker.”

She added that all but the very smallest tumors need to be treated with chemotherapy as well as the HER-2 directed agents. Patients who have larger tumors (measuring more than 2 cm) or positive lymph nodes under their arm at the time of diagnosis may be offered this type of treatment before surgery.

“We treat these patients differently as HER-2 positivity is associated with much more rapidly growing cancers,” Dr. Nerenstone said. “Ironically, however, these patients also almost always respond to the chemotherapy as well as the treatment directed at the HER-2 marker.”

She noted a “very exciting” study released recently shows that when HER-2 targeted treatment is given before surgery, the patient’s response can be analyzed at the time of surgery.

“For patients who have no residual disease, Herceptin, which targets the HER-2 marker, can be given with or without the newer drug Perjeta to complete a year of treatment,” she said. “However, for patients with cancer that has persisted, we can improve the current rates by 50 percent by giving one of the newer HER-2 targeting agents such as Kadcyla to complete a year of treatment.”

The latter drug – which also has a generic form called Ado-trastuzumab emtansine, is an antibody drug combination of Trastuzumab and the cytotoxic agent Emtansine. It can be given to patients for a complete year of treatment, Dr. Nerenstone explained.

“It’s wonderful to have the option of knowing earlier if a patient is responding as we hope, or if we need to regroup with another approach. It improves a patient’s chance of ridding themselves of the disease,” she said.

Click here for a callback from a breast health nurse navigator.

For more information on breast cancer treatment at the Hartford HealthCare Cancer Institute, click here.

 

 


What's New

Healthy Diet

Cancer Survivors: Find The Power of a Healthy Diet

By Diane Avino Dietitian Gray Cancer Center Hartford HealthCare Cancer Institute at Hartford Hospital Eating well is important during all stages of life, but it’s particularly important for cancer survivorship. Adequate nutrition is a crucial part of staying well through cancer treatments as well as promoting your long-term health. Eating...

Immunotherapy

As Cancer Treatment Evolves, a Focus on Reducing Side Effects

By Dr. Omar Eton Melanoma DMT Lead Hartford HealthCare Cancer Institute Over the past two decades, there has been great progress in understanding the relationship between cancer and the defenses a patient can muster against it. This led to a Nobel Prize for James P. Allison and Tasuku Honjo in...

Stomach Cancer

Stomach Cancer: Signs You Shouldn’t Ignore

By Dr. Bret Schipper Chief of Surgical Oncology The Hospital of Central Connecticut and MidState Medical Center Stomach, or gastric, cancer in the United States is somewhat rare, but it’s important to know the signs and symptoms. According to the American Cancer Society, about 27,500 cases of stomach cancer will...

Dr. Bret Schipper

Dr. Bret Schipper, New Surgical Oncology Chief, Starts Seeing Patients

The Hartford HealthCare Cancer Institute has announced the appointment of Dr. Bret Schipper as chief of surgical oncology at Hartford Hospital and director of oncologic surgery for the entire Cancer Institute. Dr. Schipper’s areas of interest include hepatobiliary surgery, both benign and malignant; minimally-invasive robotic surgery; soft tissue (melanoma/sarcoma) and gastric...

Senior man giving wife a kiss

Why ‘Hot Chemo’ Can Be More Effective Than IV Against Cancer

While traditional chemotherapy drips intravenously into the body to circulate and attack deadly cancer cells, a faster, a more effective way of helping people with some cancers is now available at the Hartford HealthCare Cancer Institute. Called Hyperthermic Intraperitoneal Chemotherapy (HIPEC), the treatment is designed for people with cancers of...

Pancreatic Cancer

Where a Radiation Oncologist Fits in Your Pancreatic Cancer Treatment

Treating hepatobiliary cancer involves getting the most powerful treatment directly to the source of the disease, which is where the skill of a radiation oncologist often comes in. Dr. Timothy Boyd, a radiation oncologist with Hartford Hospital and part of the Hartford HealthCare Cancer Institute’s team approach to treating pancreatic...

Chemo

Targeted Chemo Treatments Promising for HPB Patients

Everyone knows the connection between chemotherapy and cancer. It’s treatment and disease. With pancreatic cancer, maybe more than in other cancers, chemotherapy constitutes an integral part of the treatment. Medical oncologists oversee the use of chemo and other systemic treatments in patients with cancer, according to Dr. Rawad Elias, a...